

## 10 January 2022

# OMEGA DIAGNOSTICS GROUP PLC ("Omega" or the "Company" or the "Group")

# **Confirmation of detection of Omicron variant**

VISITECT® COVID-19 antigen test performs with the same high accuracy on the Omicron variant

Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Global Health (CD4 and COVID-19) and Health and Nutrition products, notes concerns regarding the ability of certain lateral flow tests to detect the Omicron variant with the same sensitivity for lower viral loads.

Further to the announcement on <a href="14">14 December 2021</a>, the Company's technology partner Mologic Ltd ("Mologic") has today re-confirmed that the Mologic Covios® Ag lateral flow test, performs with the same high accuracy on the Omicron variant as it does with existing known variants.

Mologic's studies are ongoing to determine the absolute performance of the test across the use case settings and in laboratory environments to produce a comprehensive analysis of the detection of Omicron. No data exists to suggest there is an issue, be that in silico or in trials.

This is the same test that is manufactured and sold for professional use by Omega as the VISITECT® COVID-19 antigen test.

#### Contacts:

Omega Diagnostics Group PLC

Colin King, Chief Executive Officer

Chris Lea, Chief Financial Officer

www.omegadx.com

via Walbrook PR

finnCap Ltd Tel: 020 7220 0500

Geoff Nash/Edward Whiley (Corporate Finance)
Alice Lane/ Charlotte Sutcliffe (ECM)

Walbrook PR Limited Tel: 020 7933 8780 or omega@walbrookpr.com

 Paul McManus
 Mob: 07980 541 893

 Lianne Applegarth
 Mob: 07584 391 303

 Sam Allen
 Mob: 07502 558 258

### **About Omega Diagnostics Group PLC**

Omega manufactures and distributes high quality in-vitro diagnostic products for use in hospitals, clinics, laboratories and healthcare practitioners in over 75 countries and specialise in the areas of health and nutrition and global health. www.omegadx.com